{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01220492",
      "OrgStudyIdInfo": {
        "OrgStudyId": "beijing302-002"
      },
      "Organization": {
        "OrgFullName": "Beijing 302 Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis",
      "OfficialTitle": "Phase 1/2 Study of UC-MSC Treatment for the Evaluation the Efficacy and Safety in Patients With Liver Cirrhosis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "August 2018",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 2009",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "April 2016",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "April 2016",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "October 4, 2010",
      "StudyFirstSubmitQCDate": "October 12, 2010",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 14, 2010",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "August 6, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "August 8, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Fu-Sheng Wang",
        "ResponsiblePartyInvestigatorTitle": "the Institute of Translational hepatology",
        "ResponsiblePartyInvestigatorAffiliation": "Beijing 302 Hospital"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Beijing 302 Hospital",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Liver cirrhosis (LC) represents a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and formation of regenerative nodules. The liver transplantation is one of the only effective therapies available to such patients. However, lack of donors, surgical complications, rejection, and high cost are it's serious problems. The potential for stem cells to differentiate into hepatocytes cells was recently confirmed. Particularly, autologous bone marrow-derived mesenchymal stem cell (BM-MSC) has been demonstrated to decrease MELD score and increase serum albumin in the patients with decompensated liver cirrhosis. Therefore, the investigators propose a hypothesis that umbilical cord-derived MSCs (UC-MSC) can also improve the disease conditions of LC patients, particularly reducing the decompensated conditions in these patients.",
      "DetailedDescription": "Liver cirrhosis (LC) represents a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and formation of regenerative nodules. The liver transplantation is one of the only effective therapies available to such patients. However, lack of donors, surgical complications, rejection, and high cost are it's serious problems.\n\nThe potential for stem cells to differentiate into hepatocytes cells was recently confirmed. In particular, bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation has been applicated in the clinic for treat several human diseases such as GVHD, cardiac injury and brain injury, and displayed good tolerance and efficiency. BM-MSC has also been used to treat human liver diseases such as liver failure and liver cirrhosis. In a phase 1 study, autologous BM-MSC transplantation has potential to decrease MELD score and increase serum albumin in the patients with decompensated liver cirrhosis.\n\nThe purpose of this study is to learn whether and how umbilical cord-derived MSCs (UC-MSC) can improve the longer term survival in patients with liver cirrhosis. This study will also look at how well BM-MSC is tolerated and its safety in LC patients.\n\nParticipants in the study will be randomly assigned to one of two treatment arms:\n\nArm A: Participants will receive conserved treatment plus three times UC-MSC treatment at 4-week intervals.\n\nArm B: Participants will receive conserved treatment plus three times saline infusions at 4-week intervals.\n\nUC-MSC will be prepared according to standard procedures and is collected in plastic bags containing anti coagulant. MSCs are infused intravenously. After cell therapy, patients are followed up for 75 months. The evaluation of some clinical parameters such as the level of serum alanine aminotransferase (ALT), total bilirubin (TB),prothrombin time (PT), albumin (ALB), prealbumin(PA), the rountin blood test are detected at week 12, 24, 48 timepoints. Clinical symptoms as well as complication were also observed simultaneously."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Liver Cirrhosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "liver cirrhosis",
          "mesenchymal stem cells",
          "longer term survival",
          "safety"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "266",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "conventional plus MSC treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: conventional plus MSC treatment"
              ]
            }
          },
          {
            "ArmGroupLabel": "conventional plus placebo treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: conventional plus placebo treatment"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "conventional plus MSC treatment",
            "InterventionDescription": "received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 8 weeks.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "conventional plus MSC treatment"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "conventional plus placebo treatment",
            "InterventionDescription": "received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "conventional plus placebo treatment"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "survival time",
            "PrimaryOutcomeTimeFrame": "75 months"
          },
          {
            "PrimaryOutcomeMeasure": "incidence of HCC events",
            "PrimaryOutcomeTimeFrame": "75 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "The levels of serum albumin",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "The levels of serum total bilirubin",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "The levels of serum prothrombin activity",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "the levels of serum cholinesterase",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "complications",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nLiver cirrhosis\nNegative pregnancy test (female patients in fertile age)\nwritten consent\n\nExclusion Criteria:\n\nHepatocellular carcinoma or other malignancies\nPregnancy\nsepsis\nPresence of significant extrahepatic biliary disease (e.g. CBD stone, PSC, etc.)\nCardiac, renal or respiratory failure\nActive thrombosis of the portal or hepatic veins",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Fu-Sheng Wang, Professor",
            "OverallOfficialAffiliation": "Beijing 302 Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Beijing 302 Hospital",
            "LocationCity": "Beijing",
            "LocationState": "Beijing",
            "LocationZip": "100039",
            "LocationCountry": "China"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "18328931",
            "ReferenceType": "background",
            "ReferenceCitation": "Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008 Mar 8;371(9615):838-51. doi: 10.1016/S0140-6736(08)60383-9. Review."
          },
          {
            "ReferencePMID": "20495456",
            "ReferenceType": "background",
            "ReferenceCitation": "Kisseleva T, Gigante E, Brenner DA. Recent advances in liver stem cell therapy. Curr Opin Gastroenterol. 2010 Jul;26(4):395-402. doi: 10.1097/MOG.0b013e32833a6bec. Review."
          },
          {
            "ReferencePMID": "19455046",
            "ReferenceType": "background",
            "ReferenceCitation": "Kharaziha P, Hellstr√∂m PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009 Oct;21(10):1199-205. doi: 10.1097/MEG.0b013e32832a1f6c."
          },
          {
            "ReferencePMID": "17903050",
            "ReferenceType": "result",
            "ReferenceCitation": "Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, Baharvand H, Ghavamzadeh A, Malekzadeh R. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007 Oct;10(4):459-66. Erratum in: Arch Iran Med. 2008 Jan;11(1):135."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008103",
            "ConditionMeshTerm": "Liver Cirrhosis"
          },
          {
            "ConditionMeshId": "D000005355",
            "ConditionMeshTerm": "Fibrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000008107",
            "ConditionAncestorTerm": "Liver Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10255",
            "ConditionBrowseLeafName": "Liver Cirrhosis",
            "ConditionBrowseLeafAsFound": "Liver Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafAsFound": "Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10259",
            "ConditionBrowseLeafName": "Liver Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M10262",
            "InterventionBrowseLeafName": "Liver Extracts",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}